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Summary 
The oral and maxillofacial surgeons are frequently asked to manage 
patients who are receiving oral anticoagulants. The goal of treatment is to 
minimize the risk of hemorrhage while continuing to protect the patient against 
thromboembolism formation. The ordinary treatment includes the interruption of 
anticoagulant therapy for oral surgery interventions to prevent hemorrhage. 
However, this practice may logically increase the risk of a potentially life-
threatening thromboembolism. Thus, this issue is still controversial. 
Aim of this study is to review the evidence of different therapy approach, 
to highlight the areas of major concern, and to suggest specific oral surgery 
treatment for patients on oral anticoagulants. 
A Medline and an extensive hand search were performed on English-
language publications beginning in 1971 till now. The pertinent literature and 
clinical protocols of hospital dentistry departments have been extensively 
reviewed, presented and discussed. 
Several evolving clinical practices in the last years have been detected:  
- anticoagulant use is generally not discontinued;  
- oral surgery is performed despite laboratory values showing significant 
bleeding tendency;  
- new effective local haemostatic modalities are used to prevent bleeding; 
- patients at risk are referred to hospital-based clinics. 
The management of oral surgery procedures on patients treated with 
anticoagulants should be influenced by several factors: laboratory values, extent 
and urgency of the intervention, treating physician’s recommendation, available 
facilities, dentist expertise, and patient’s oral, medical, and general condition. 
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Introduction  
Thrombosis is the formation, from the components of blood, of an 
abnormal mass within the vascular system. It involves the interaction of vascular, 
cellular, and humoral factors within a flowing stream of blood. Thrombosis and 
the complicating emboli that can result are among the most important causes of 
sickness and death in developed countries. 
Thrombosis is of greater overall clinical importance in terms of morbidity 
and mortality than all of the hemorrhagic disorders combined.  
Excessive activation of coagulation or inhibition of anticoagulant 
mechanisms may result in hypercoagulability and thrombosis. Injury to the vessel 
wall, alterations in blood flow, and changes in the composition of blood are major 
factors leading to thrombosis.  
Thrombotic disorders can be caused by an inherited deficiency of 
antithrombin III, heparin cofactor II,protein C, protein S, thrombomodulin, 
plasminogen, or tissue plasminogen activator; an activated protein C resistance 
(factor V Leiden); dysfibrinogenemia; and homocysteinemia.  
Most of these disorders have also been reported as acquired conditions.  
The rice for time and money in the everyday and ordinary life has 
implication on the human health, which resulted with increased number of 
cardiovascular diseases in the young population, and with the effect and 
consequences as a socio-economical problem.  
The scientific literature, the rapid development and the use of new 
scientific clinical methods of laboratory investigations changed the oral surgery 
treatment for the patients on oral anticoagulants. 
Antithrombotic agents 
The antithrombotic medicaments are antiplatelet, anticoagulant and 
thrombolytic agents.  
Antiplatelet drugs are used to prevent and / or treat thromboembolic 
disorders, which play a key role in cardiovascular diseases. Given the fact that 
the antiaggregant mechanism of action consists in inhibiting the platelet function 
by preventing aggregation, the initial phase of haemostasis, use of these drugs 
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can make patients more susceptible to haemorrhages. This is of vital importance 
in the daily practice of dentists, particularly when performing surgery, such as 
dental extractions. Over the last few years the recommendation has been to 
continue with the antiplatelet therapy during dental extractions. There is little 
literature referring to dental extractions in patients taking antiplatelet drugs, and 
the majority of the studies available exclusively, or almost exclusively, refer to the 
use of aspirin or acetylsalicylic acid  it is actually the most used antiplatelet drug. 
The term oral anticoagulant (OAC) refers to oral vitamin K antagonists, 
including mainly sodium warfarin (the most widely used agent in Anglo-Saxon 
countries) and acenocoumarol (widely used in some countries of Europe). These 
drugs are widely prescribed for preventing arterial thromboembolism in patients 
with atrial fibrillation and/or heart valve prostheses, and for the treatment and 
prevention of deep venous thrombosis and pulmonary embolism Oral 
anticoagulants (OA) inhibits the enzyme vitamin K epoxide reductase, which 
converts vitamin K to vitamin K hydroquinone. The vitamin K hydroquinone is 
needed to gamma carboxylate the glutamic acids at the N-terminal portion of the 
clotting factors II, VII, IX, and X and endogenous proteins C and S. If the clotting 
factors are not carboxylated, they are not biologically active. Return of normal 
clotting after stopping OA requires the elimination of OA followed by the 
synthesis of new clotting factors. Because the elimination half-life of OA is 40 
hours and the clotting factors have different and sometimes long half-lives, it 
takes days to reverse the effects of OA. 
Oral anticoagulans act by blocking the ability of Vitamin K to carboxylate 
the Vitamin K dependent clotting factors, thereby reducing their coagulant 
activity. OA works by interfering with internal recycling of oxidized Vitamin K to 
the reduced form. When OA are given, the oxidized form of Vitamin K builds up 
in the blood leading to a deficiency of reduced Vitamin K and a decrease in 
carboxylation of prothrombin. OA interferes with g–carboxylation of terminal 
glutamic acids on the procoagulant proteins, Factors II, VII, IX, and X. 
The antiplatelet and anticoagulant agents have been extensively 
researched and developed as potential therapies for prevention and 
4 
 
management of arterial and venous thrombosis. Also, these drugs have been 
associated with prolongation of bleeding after oral surgery interventions. Thus, 
some of the oral surgeon still recommend to stop antiplateled and oral 
anticoagulants at last 3 days before any kind of oral surgery procedure.  
However, stopping these drugs before the interventions expose the patient 
to vascular problems, and with potential of significant morbidity.  
The handling of these drugs requires correct monitorization and dose 
adjustment to obtain the desired therapeutic effect while minimizing the adverse 
effects associated both with excessive anticoagulation (which leads to bleeding) 
and with insufficient antithrombotic action (which can produce thrombosis). 
Aim 
The aim of this study is to review the evidence of different therapy 
approach, to highlight the areas of major concern, and to suggest specific oral 
surgery treatment for patients on oral anticoagulants. 
Oral anticoagulants – withdraw or continuing  
The oral and maxillofacial surgeons are frequently asked to manage 
patients who are receiving oral anticoagulants. The goal of treatment is to 
minimize the risk of hemorrhage while continuing to protect the patient against 
thromboembolism formation. The ordinary treatment includes the interruption of 
anticoagulant therapy for oral surgery interventions to prevent hemorrhage. 
However, this practice may logically increase the risk of a potentially life-
threatening thromboembolism. Thus, this issue is still controversial. 
Assael said that the haemostasis care of the oral anticoagulated patients 
is a shared responsibility and oral and maxillofacial surgeons, and the 
hematology/coagulation team huddle to determine the steps.  
The surgeon is faced with the choice of altering or stopping oral 
anticoagulants and risking thromboembolism or leaving the patient on the oral 
anticoagulants and risking uncontrolled bleeding. A common approach to 
managing patients with a low risk of thromboembolism needing surgery is to 
interrupt oral anticoagulans therapy for several days before and after surgery. 
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Patients with a high risk of thromboembolism commonly stop OA and bridge 
anticoagulation with unfractionated heparin (UHF) or low-molecular-weight 
heparin (LMWH). 
The anticoagulant effect in turn depends on the half-life of the inhibited 
factors. In this sense, the half-lives of factors VII, IX, X and II are 6, 24, 40 and 60 
hours, respectively. Blood coagulation factor VII is the first to be affected, 
prolonging prothrombin time (PT). Factors IX, X and II are posteriorly affected: 
factor IX prolongs activated partial thromboplastin time (aPTT), while factors X 
and II prolong both PT and aPTT. These are well tolerated drugs, with rapid 
absorption via the oral route. The peak plasma concentrations are reached one 
hour after administration, though the reduction in coagulation factors takes place 
48-72 hours after dosing. The half-life of warfarin is 48-72 hours, versus 8-10 
hours in the case of acenocoumarol. Thus, the effects of warfarin are longer 
lasting in terms of both the induction and disappearance of therapeutic action.  
However, patients who interrupt oral anticoagulants therapy are at risk of 
developing a thromboembolism with or without bridging therapy. On the other 
hand, oral anticoagulants therapy can be continued without interruption for 
procedures such as dentoalveolar surgeries that rarely cause significant or life-
threatening bleeding. Stopping oral anticoagulants is problematic because of its 
slow unpredictable reversal. 
Interruption of Oral Anticoagulant Therapy and Risk of Thrombotic 
Episode 
The risk for thromboembolism depends on several factors, including the 
clinical indications for anticoagulation. Anticoagulation is required in the 
management of patients with prosthetic heart valves, chronic atrial fibrillation, 
hypercoagulable states (ie, protein C deficiency, protein S deficiency, factor V 
Leiden mutation, antithrombin III deficiency, antiphospholipid-antibody 
syndrome), venous or arterial thromboembolism, and cerebrovascular disease 
with strokes. However, patients who require anticoagulation do not have equal 
risk of developing thromboembolism. 
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 The goal of managing anticoagulated patients who need surgery is to 
prevent major or life-threatening bleeding while protecting against 
thromboembolism. 
Some procedures such as intra-abdominal, intrathoracic, major cancer 
surgery, removal of head and neck tumors, and extra oral open reduction of 
facial fractures are associated with considerable bleeding.  
Some patients are particularly sensitive to OACs, and the activity of these 
drugs moreover can be affected by a range of factors including individual patient 
response, diet, or the simultaneous administration of other commonly used drugs 
such as antibiotics, analgesics, or even herbal remedies. As a result, regular 
monitorization is required, and such control must be more frequent when 
changes occur in any of the aforementioned aspects (3,5). OAC action is 
monitored on the basis of the effect of such drugs on prothrombin time (PT), i.e., 
the time required for the clotting of citrate-treated plasma, after adding calcium 
and thromboplastin. Thromboplastin is extracted from different tissues with 
different levels of sensitivity - a fact that complicates the comparison of PT test 
results. The PT results are usually reported as the ratio patient time / control 
time. The simple ratio is extremely variable, depending on the sensitivity of the 
reagent used - thus making it impossible to establish universally applicable 
therapeutic margins.  
For this reason, in 1978 the World Health Organization (WHO) 
recommended PT standardization, and in 1983 it introduced the INR 
(international normalized ratio), which is calculated by raising the simple ratio to 
the international sensitivity index (ISI) of the thromboplastin used.  
Thus, INR = (patient time / control time) ISI.  
This is the formula used to standardize PT, allowing comparison 
regardless of the thromboplastin used by the different laboratories, and ensuring 
increased reliability in monitoring OAC treatment. At the same time, the different 
international societies established recommendations regarding the therapeutic 
anticoagulation levels to be maintained according to the existing patient 
pathology - the corresponding INR value ranging from 2 to 3.5. Because of that 
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there is a strong correlation between INR and bleeding risk - the latter increasing 
when INR >4 (Table 1).  
Table 1. Therapeutic anticoagulation levels 
 
Clinical pathology INR INR 
- Prophylaxis – venous thromboembolism (high risk surgery) 
- Prophylaxis – venous thromboembolism (hip surgery) 
- Treatment of deep venous thrombosis or pulmonary embolism 
- Prevention of systemic embolism in patients with atrial fibrillation, heart 
valve disease, bioprostheses, or acute myocardial infarction 
- Valve prostheses, recurrent systemic embolism, recurrent myocardial 
infarction 
2.0-3.0 
2.0-3.0 
2.0-3.0 
2.0-3.0 
 
2.5-3.5 
 
INR = international normalized ratio 
.  
The recommendations vary according to the bleeding risk of the surgical 
intervention and the indication of anticoagulation therapy (i.e., the 
thromboembolic risk of the patient). Thus, for example, treatment to prevent 
venous thromboembolism is not the same as treatment for dealing with an acute 
thrombotic episode.  
Although consensus is lacking, the expert groups do establish a series of 
recommendations: 
1. For patients at low risk of bleeding after the operation, anticoagulation can be 
maintained at the lower limit of the therapeutic range (INR = 2.0). 
2. For patients at high bleeding risk, anticoagulation should be maintained at 
subtherapeutic levels (INR = 1.5). Accordingly, acenocoumarol should be 
suspended 3-4 days before surgery (4-5 days in the case of warfarin). On day -3, 
low molecular weight heparin (LMWH) should be provided at therapeutic, 
medium or prophylactic doses, depending on whether the thrombotic risk of the 
patient is high, moderate or low, respectively. This is to be maintained until 12 
hours before surgery, followed 12 hours after surgery be reintroduction of the 
original treatment, provided there is no bleeding. 
Bridging Therapy 
Life threatening or major bleeding in patients who need high-risk surgery 
is avoided by stopping oral anticoagulants with or without bridging therapy. The 
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Food and Drug Administration has not approved bridging therapy with LMWH in 
patients with prosthetic heart valves, and UFH is frequently recommended for 
bridging therapy in these high-risk patients who develop arterial 
thromboembolism.  
Bridging with UFH or LMWH is done to shorten the interval of sub 
therapeutic anticoagulation while waiting for the reversal of oral anticoagulation. 
For patients with a low risk of thromboembolism, bridging is not recommended 
because the efficacy of bridging with UFH and LMWH does not outweigh the risk 
of postoperative bleeding.  
Patients with a low risk of thromboembolism can stop the oral 
anticoagulant and restart it after the surgery. Stopping oral anticoagulant and 
bridging is not recommended for procedures for which major bleeding is not likely 
to develop.  
Depending on the existing thromboembolic risk, the American Heart 
Association / American College of Cardiology Foundation Guide to Warfarin 
Therapy recommends different heparin management regimens for the patients 
with moderate, high and low thromboembolic risk. In general, heparins are not 
reintroduced before 12 hours post surgery, and dosing is postponed for longer 
periods in the case of evidence of bleeding. 
 
Oral Surgery Procedures and management of bleeding 
The management of oral surgery procedures on patients treated with 
anticoagulants should be influenced by several factors: laboratory values, extent 
and urgency of the intervention, treating physician’s recommendation, available 
facilities, dentist expertise, and patient’s oral, medical, and general condition and 
atibiotic profilaxis. 
Procedures including single and multiple dental extractions, full mouth 
extractions, and alveolectomies are associated with very few bleeding episodes 
in patients who continue oral anticoagulans therapy.  
Wahl published a review of perioperative management of patients 
receiving oral anticoagulants in 1998. He summarized the outcome of 2,014 
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dental surgical procedures in patients who continued oral anticoagulation. 
Serious bleeding occurred in only 12 of the procedures, and 5 of the 12 bleeds 
were associated with INRs above therapeutic levels. Wahl also examined reports 
including 493 patients who discontinued warfarin; 5 of these patients developed 
serious thromboembolic complication, resulting in 4 deaths. He concluded that as 
long as the surgery was done when the INR was within therapeutic range, 2.0 to 
4.0, the chance of serious bleeding following dentoalveolar surgery was low in 
patients who continue their oral anticoagulation therapy. 
Martinowitz et al. followed 40 patients having 63 teeth removed without 
altering the oral anticoagulation. Local hemostasis was obtained using a 
biological adhesive after placing thrombin soaked gauze into the socket for 3 
minutes. The INRs on the day of surgery ranged from 2.5 to 4.0. There were no 
incidences of prolonged or excessive bleeding. One patient had hemorrhage on 
the third postoperative day that was controlled by biting on gauze.  
In Sindet–Pedersen’s original article, anti-coagulant-treated patients 
undergoing oral surgery, were prescribed a 4.8% aqueous solution of tranexamic 
acid for seven days post-surgery to prevent re-bleeding secondary to fibrinolysis 
of the wound clot.  
The results of the most scientific studies confirm that anticoagulation 
treatment with warfarin need not be withdrawn prior to dental extractions, 
provided that the patients do not have a preoperative INR value greater than 4.0, 
and local measures including antifibrinolytic therapy is instituted. 
Recently, some authors have recommended that most anticoagulated 
patients are capable of withstanding routine, limited, oral surgery procedures 
without additional medical intervention such as an antifibrinolytic mouthwash 
provided a good surgical technique is employed. However, they limit acceptable 
INR values for this proposal to 3.0 or less when clearly there are patients with 
therapeutic levels higher than 3.0 and this group tends to comprise those most at 
risk of serious thromboembolic events if their anticoagulation is temporarily 
discontinued or decreased such as prosthetic mitral valve replacement. A 4.8% 
tranexamic acid mouthwash is effective in controlling local haemostasis in 
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anticoagulated patients undergoing dental extractions. Statistically there appears 
to be no difference between a prescribed two-day vs a five-day course. 
The usage of Surgicel in the scientific studies is very common, because it 
is widely available, easy to handle, inexpensive and acts as a good delivery 
vehicle for the tranexamic acid deep into the base of the tooth sockets and 
subsequent blood clot after surgery. Surgicel is an oxidized regenerated cellulose 
preparation whose local haemostatic action depends on the binding of 
haemoglobin to oxycellulose, allowing the dressing to expand into a gelatinous 
mass, which in turn acts both as scaffolding for clot formation and a clot 
stabilizer. The material is completely absorbable and does not interfere with 
healing or bone regeneration. 
In 2003, Carter et al. conducted a randomized study in patients under oral 
anticoagulation and subjected to extractions without modifying the OAC regimen, 
and applying two types of hemostatic agents (4.8% tranexamic acid and 
autologous fibrin adhesive). The authors concluded that both approaches are 
effective and safe in controlling post-extraction bleeding.  
Autologous fibrin adhesive applied to the socket walls in turn was 
recommended when the patient has difficulties performing rinses correctly. 
Posterior studies reported the same efficacy in controlling hemostasis by 
applying rinses for only two days (17). Tranexamic acid has no marketing license 
in some countries, and fibrin adhesives are not recommended by all authors, due 
to the risk of disease transmission - though such systems are subjected to viral 
inactivation processes - and their high cost. 
Post-extraction bleeding is generally controlled by local measures such as 
socket curettage, suturing, and local compression, thanks to easy access to the 
bleeding zone. 
When such measures prove insufficient, and the anticoagulation effect 
must be suppressed, this can be done by administering vitamin K. In this sense, 
intravenous administration elicits faster effects than the oral route – the 
recommended dose being 5-10 mg. The use of concentrates of prothrombin 
complex or fresh frozen plasma is reserved for cases of important bleeding.  
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Based on the evidence that the benefit of preventing thromboembolism 
outweighs the risk of bleeding, the recommendations of the published clinical 
studies and the expert opinions are to keep the OAC dose unchanged, working 
with therapeutic INR levels, and adopting local hemostatic measures - with the 
use of antifibrinolytic agents such as tranexamic acid, in dental extractions. More 
invasive oral surgery with an increased bleeding risk may constitute an exception 
to these guidelines, requiring due evaluation in coordination with the 
hematologist. 
Recommendations and conclusions 
The evidence from clinical trials and focused reviews supports continuing 
oral anticoagulation for patients needing dentoalveolar surgery. As long as the 
INR is within the therapeutic range and local hemostatic measures are taken 
following the surgery, these patients will have little chance of developing 
uncontrolled bleeding following the surgery. 
Stopping warfarin with or without bridging for dentoalveolar surgery is not 
supported by clinical evidence. The risk of developing life-threatening bleeding or 
bleeding that cannot be controlled using local measures following dental 
extractions, alveoloplasties, or dental implants is so low that there is no need to 
stop warfarin. 
Local hemostasis will control the bleeding in the few patients who develop 
postsurgical bleeding. The risk of uncontrolled life threatening bleeding following 
dentoalveolar surgery is so low that it is not necessary to stop anticoagulation 
even for a short interval and risk thromboembolism in patients on oral 
anticoagulants. 
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